These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

669 related items for PubMed ID: 28847249

  • 21. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M, ASSERT Team.
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [Abstract] [Full Text] [Related]

  • 22. Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
    de Boissieu P, Dramé M, Raffi F, Cabie A, Poizot-Martin I, Cotte L, Garraffo R, Delobel P, Huleux T, Rey D, Bani-Sadr F, Dat’AIDS Study Group.
    Medicine (Baltimore); 2016 Sep; 95(37):e4890. PubMed ID: 27631261
    [Abstract] [Full Text] [Related]

  • 23. An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
    M Llibre J, Raffi F, Moyle G, Behrens G, Bouee S, Reilly G, Borg P, Piontkowsky D, Rogatto F.
    PLoS One; 2016 Sep; 11(5):e0155406. PubMed ID: 27196332
    [Abstract] [Full Text] [Related]

  • 24. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW, Horvath H.
    PLoS One; 2016 Sep; 11(10):e0162775. PubMed ID: 27736859
    [Abstract] [Full Text] [Related]

  • 25. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
    Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, Chen H, Zang N, Liao Y, Ye L, Liang H.
    AIDS Res Ther; 2016 Sep; 13(1):30. PubMed ID: 27617024
    [Abstract] [Full Text] [Related]

  • 26. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
    Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R, Wang H, ROCKET 1 (Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial) Study Group.
    PLoS One; 2015 Sep; 10(2):e0116297. PubMed ID: 25658097
    [Abstract] [Full Text] [Related]

  • 27. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
    Curran A, Martinez E, Podzamczer D, Lonca M, Barragan P, Crespo M, Falco V, Vidal-Sicart S, Imaz A, Martinez M, Gatell JM, Ribera E.
    Antivir Ther; 2012 Sep; 17(4):711-8. PubMed ID: 22374987
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
    Butler K, Anderson SJ, Hayward O, Jacob I, Punekar YS, Evitt LA, Oglesby A.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
    [Abstract] [Full Text] [Related]

  • 29. Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis.
    Alzate Angel JC, Duque Molina MM, García García HI.
    Colomb Med (Cali); 2017 Jun 30; 48(2):70-81. PubMed ID: 29021641
    [Abstract] [Full Text] [Related]

  • 30. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial.
    Wang R, Sun L, Wang X, Zhai Y, Wang L, Ma P, Wu C, Zhou Y, Chen R, Wang R, Zhang F, Hua W, Li A, Xia W, Gao Y, Li R, Lv S, Shao Y, Cao Y, Zhang T, Wu H, Cai C, Dai L.
    Clin Infect Dis; 2024 Jul 19; 79(1):169-176. PubMed ID: 38236137
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
    Suárez-García I, Alejos B, Ruiz-Algueró M, García Yubero C, Moreno C, Bernal E, Pérez-Is L, Zubero Z, de Zárraga Fernández MA, Samperiz Abad G, Jarrín I, Cohort of the Spanish HIV/AIDS Research Network (CoRIS).
    J Int AIDS Soc; 2021 Jul 19; 24(7):e25758. PubMed ID: 34291580
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 35. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR, CANOC Collaboration.
    J Acquir Immune Defic Syndr; 2011 Sep 01; 58(1):38-46. PubMed ID: 21709570
    [Abstract] [Full Text] [Related]

  • 36. Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
    Floridia M, Pinnetti C, Ravizza M, Masuelli G, Personeni C, Sansone M, Degli Antoni A, Guaraldi G, Spinillo A, Tassis B, Dalzero S, Liuzzi G, Tamburrini E.
    J Acquir Immune Defic Syndr; 2018 May 01; 78(1):99-104. PubMed ID: 29406430
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A, Conti F, Pezzati L, Oreni L, Ridolfo AL, Morena V, Bonazzetti C, Pagani G, Formenti T, Galli M, Rusconi S.
    BMC Infect Dis; 2021 Jun 22; 21(1):595. PubMed ID: 34157984
    [Abstract] [Full Text] [Related]

  • 40. Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life.
    Mejías-Trueba M, Gutierrez-Valencia A, Llaves-Flores S, Roca-Oporto C, Herrero M, Sotomayor de la Piedra C, Lopez-Cortes LF, Espinosa N.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0065424. PubMed ID: 38916326
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.